N6-(氨基羰基)-N2-[芴甲氧羰基]-L-赖氨酸 | 201485-17-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: N6-(氨基羰基)-N2-[芴甲氧羰基]-L-赖氨酸
• 中文别名: 芴甲氧羰基-L-高胍氨酸
• 英文名称: N6-carbamoyl-N2-{[(9H-fluoren-9-yl)methoxy]carbonyl}-L-lysine
• 英文别名: (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-6-ureidohexanoic acid；(2S)-6-(carbamoylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
• CAS: 201485-17-8
• 化学式: C₂₂H₂₅N₃O₅
• 分子量: 411.458
• InChiKey: VJZUCXPETVPQIB-IBGZPJMESA-N

物化性质

• 沸点：
  676.0±55.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  30
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  131
• 氢给体数：
  4
• 氢受体数：
  5

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (S)-di-tert-butyl 2-(3-((S)-6-amino-1-(tert-butoxy)-1-oxohexan-2-yl)ureido)pentanedioate 、 N6-(氨基羰基)-N2-[芴甲氧羰基]-L-赖氨酸 在 N-甲基吗啉 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以310 mg的产率得到tri-tert-butyl (5S,12S,16S)-5-[4-(carbamoylamino)butyl]-1-(9H-fluoren-9-yl)-3,6,14-trioxo-2-oxa-4,7,13,15-tetraazaoctadecane-12,16,18-tricarboxylate
  参考文献：
  名称：

  [EN] TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
  [FR] PRODUITS RADIOPHARMACEUTIQUES CIBLÉS POUR LE DIAGNOSTIC ET LE TRAITEMENT DU CANCER DE LA PROSTATE

  摘要：

  通用式(I)的化合物：其中：n为1、2或3；R1、R2、R3和R4独立地代表OH或Q；Q代表从群组中选择的组织靶向基团，或其立体异构体、水合物、溶剂合物、盐或其混合物，制备所述化合物的方法，用于制备所述化合物的中间化合物，包含所述化合物的药物组合物和组合物，以及用于制造用于治疗或预防疾病的药物组合物的所述化合物的用途，特别是软组织疾病的治疗或预防，作为唯一药剂或与其他活性成分结合使用。

  公开号：

  WO2021013978A1

文献信息

• NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF
  申请人：Boyd A. Vincent

  公开号：US20070021434A1

  公开（公告）日：2007-01-25

  The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides methods for identifying amide-based, non-nucleoside compounds having antiviral activity.

  本公开提供了基于酰胺的非核苷类化合物，具有抗Hepacivirus活性，例如丙型肝炎病毒（HCV），合成这类化合物的方法和中间体，以及在各种情境中使用这些化合物的方法，包括在治疗和预防病毒感染中的应用。本公开还提供了识别具有抗病毒活性的基于酰胺的非核苷类化合物的方法。
• COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
  申请人：Cameron Dale Russell

  公开号：US20080171783A1

  公开（公告）日：2008-07-17

  The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.

  本公开提供了基于酰胺的非核苷类化合物，具有对内源聚合酶（如聚合酶α和聚合酶γ）的抑制活性。本公开进一步提供了用于治疗过度增殖性疾病或疾病的用途，例如良性或恶性肿瘤，更具体地是对聚合酶α和聚合酶γ抑制敏感的癌症。
• Thrombospondin 1-binding peptide
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US11149066B2

  公开（公告）日：2021-10-19

  Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia. Specifically provided is a macrocyclic polypeptide represented by formula (I) [wherein A is selected from the linking groups A1 to A6; Xaa1 is a residue of an aliphatic amino acid, an aromatic amino acid, a basic amino acid, a neutral amino acid, or an acidic amino acid, or is absent; Xaa2 is a residue of an aromatic amino acid or a neutral amino acid; Xaa3 is a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid; Xaa4 is Ser, Thr, Ala, or mS; Xaa5 is Gly or Ser; Xaa6 is a residue of a basic amino acid or a neutral amino acid; Xaa7 is a residue of a neutral amino acid or an acidic amino acid; Xaa8 is a residue of an aromatic amino acid; Xaa9 is a residue of an aliphatic amino acid, a neutral amino acid, or an aromatic amino acid; Xaa10 is a residue of a basic amino acid, an aliphatic amino acid, an aromatic amino acid, or a neutral amino acid; Xaa11 is a residue of an aromatic amino acid; and Xaa12 is a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid], or a pharmacologically acceptable salt thereof.

  本发明提供了一种化合物，该化合物可通过抑制 TSP1 的功能促进血管生成，并可用于治疗或预防危重肢体缺血等疾病。 具体而言，提供了一种由式（I）代表的大环多肽 [其中 A 选自连接基团 A1 至 A6；Xaa1 是脂肪族氨基酸、芳香族氨基酸、碱性氨基酸、中性氨基酸或酸性氨基酸的残基，或者不存在；Xaa2 是芳香族氨基酸或中性氨基酸的残基；Xaa3 是脂肪族氨基酸、芳香族氨基酸或碱性氨基酸的残基； Xaa4 是 Ser、Thr、Ala 或 mS； Xaa5 是 Gly 或 Ser； Xaa6 是碱性氨基酸或中性氨基酸的残基；Xaa7 是中性氨基酸或酸性氨基酸的残基； Xaa8 是芳香族氨基酸的残基； Xaa9 是脂肪族氨基酸、中性氨基酸或芳香族氨基酸的残基；Xaa10 是碱性氨基酸、脂肪族氨基酸、芳香族氨基酸或中性氨基酸的残基； Xaa11 是芳香族氨基酸的残基；以及 Xaa12 是脂肪族氨基酸、芳香族氨基酸或碱性氨基酸的残基]，或其药理学上可接受的盐。
• THROMBOSPONDIN 1-BINDING PEPTIDE
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20200131230A1

  公开（公告）日：2020-04-30

  Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia. Specifically provided is a macrocyclic polypeptide represented by formula (I) [wherein A is selected from the linking groups A 1 to A 6 ; X aa1 is a residue of an aliphatic amino acid, an aromatic amino acid, a basic amino acid, a neutral amino acid, or an acidic amino acid, or is absent; X aa2 is a residue of an aromatic amino acid or a neutral amino acid; X aa3 is a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid; X aa4 is Ser, Thr, Ala, or m S; X aa5 is Gly or Ser; X aa6 is a residue of a basic amino acid or a neutral amino acid; X aa7 is a residue of a neutral amino acid or an acidic amino acid; X aa8 is a residue of an aromatic amino acid; X aa9 is a residue of an aliphatic amino acid, a neutral amino acid, or an aromatic amino acid; X aa10 is a residue of a basic amino acid, an aliphatic amino acid, an aromatic amino acid, or a neutral amino acid; X aa11 is a residue of an aromatic amino acid; and X aa12 is a residue of an aliphatic amino acid, an aromatic amino acid, or a basic amino acid], or a pharmacologically acceptable salt thereof.
• [EN] TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER<br/>[FR] PRODUITS RADIOPHARMACEUTIQUES CIBLÉS POUR LE DIAGNOSTIC ET LE TRAITEMENT DU CANCER DE LA PROSTATE
  申请人：BAYER AS

  公开号：WO2021013978A1

  公开（公告）日：2021-01-28

  A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

  通用式(I)的化合物：其中：n为1、2或3；R1、R2、R3和R4独立地代表OH或Q；Q代表从群组中选择的组织靶向基团，或其立体异构体、水合物、溶剂合物、盐或其混合物，制备所述化合物的方法，用于制备所述化合物的中间化合物，包含所述化合物的药物组合物和组合物，以及用于制造用于治疗或预防疾病的药物组合物的所述化合物的用途，特别是软组织疾病的治疗或预防，作为唯一药剂或与其他活性成分结合使用。